Testing a new drug with chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a drug called CB-839 to standard chemoradiation (cisplatin and radiation) can improve outcomes for people with advanced cervical cancer when it cannot be treated with surgery. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have newly diagnosed cervical cancer that is stage III or IVA.
- You have not had radiation therapy to the pelvis before.
- You are not currently being treated for another active cancer.
- You are able to take the study drugs cisplatin and CB-839.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This study tests a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) given alongside radiation therapy for people with locally advanced cervical cancer. The goal is to see if this combination is safe and effective in shrinking the cancer and improving outcomes.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.